NEW YORK, Aug. 27, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against C3.ai, Inc.  ("C3" or the "Company") (NYSE: AI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether C3 and certain of its officers and/or directors hav ...

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the C3.ai class action lawsuit – captioned Liggett v. C3.ai, Inc., No. 25-cv-07129 (N.D. Cal.) – seeks to represent purchasers or acquirers of C3.ai, Inc. (NYSE: AI) securities and charges C3.ai and certain of C3.ai’s executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the C3.ai class action lawsuit, please provide your informat ...

NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP is notifying investors about a securities class action lawsuit against C3.ai, Inc. ( NYSE: AI) (“C3.ai” or the “Company”). PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION C.ai, Inc. Class Action Lawsuit Summary Class Period: February 26, 2025 – August 8, 2025Court: United States District Court for the Northern District of CaliforniaLead Plaintiff Deadline: October 21, 2025 Allegations: The lawsuit allege ...

NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in C3.ai, Inc. ("C3.ai" or the "Company") (NYSE: AI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of C3.ai investors who were adversely affected by alleged securities fraud between February 26, 2025 and August 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/c3-ai-inc-lawsuit-submission-form?prid=163455 ...

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. for allegedly misleading investors about the impact of its CEO's health on the company's business prospects [1][2]. Group 1: Allegations and Impact - The lawsuit claims that C3.ai failed to disclose how the CEO's health affected the company's ability to close deals and that management was ineffective in mitigating this impact [2]. - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing the poor performance to "the reorganization with new leadership" and the CEO's health issues [3]. - Following this announcement, C3.ai's stock price dropped from $22.13 per share on August 8, 2025, to $16.47 per share on August 11, 2025, marking a decline of over 25% [3]. Group 2: Legal Proceedings - Shareholders interested in serving as lead plaintiffs in the class action must submit their papers to the court by October 21, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 3: Company Background - Robbins LLP, the firm handling the case, has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5].

PHILADELPHIA, Aug. 25, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against C3.ai, Inc. (NYSE: AI) ("C3.ai" or the "Company") on behalf of investors who purchased or acquired shares during the period from February 26, 2025, through August 8, 2025 (the "Class Period").Investor Deadline: Investors who purchased or acquired C3.ai securities during the Class Period may, no later than October 21, 2025, seek to be appointed as a lead plaintiff representati ...

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired C3.ai, Inc. (“C3.ai” or the “Company”) (NYSE: AI) between February 26, 2025 and August 8, 2025, inclusive (the “Class Period”). The Complaint alleges that Defendants created the false impression that they possessed reliable infor ...

Core Viewpoint - A shareholder has filed a securities class action lawsuit against C3.ai, Inc. for alleged misrepresentations regarding the company's business and the impact of the CEO's health on its operations [1][2]. Group 1: Lawsuit Details - The lawsuit claims that C3.ai's management failed to address the significant impact of the CEO's health on the company's ability to close deals and execute its profit and growth potential [2]. - Investors who purchased C3.ai securities between February 26, 2025, and August 8, 2025, are included in the class [1]. Group 2: Legal Process - Interested parties wishing to serve as lead plaintiff must file papers by October 21, 2025, and representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large public and private pension funds [4].

Small deep value individual investor, with a modest private investment portfolio, split approx. 50%-50% between shares and call options. I have a B.Sc. in aeronautical engineering and over 6 years of experience as an engineering consultant in the aerospace sector. The latter statement is not relevant in any way whatsoever to my investment style, but I thought to add it for self-indulgent purposes. I have a contrarian investment style, highly risky, and often dealing with illiquid options. How illiquid? Well ...

ATLANTA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against C3.ai, Inc. (“C3” or the “Company”) (NYSE: AI). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding the true state of C3’s growth; specifically, that its CEO’s health was having a significant impact on C3’s ability to close deals. If you purchased shares of C3 between February 26, 2025 and August 8, 2025, and ...